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The ICH M7 guideline describes a consistent approach to identify, categorize, and control DNA reactive,
mutagenic, impurities in pharmaceutical products to limit the potential carcinogenic risk related to such
impurities. This paper outlines a series of principles and procedures to consider when generating (Q)SAR
assessments aligned with the ICH M7 guideline to be included in a regulatory submission. In the absence
of adequate experimental data, the results from two complementary (Q)SAR methodologies may be
combined to support an initial hazard classiﬁcation. This may be followed by an assessment of additional
information that serves as the basis for an expert review to support or refute the predictions. This papers in this manuscript have not
ot be construed to represent
f commercial products, their
eported herein is not to be
ent of such products by the
pe, Inc., 1393 Dublin Road,
t).
r Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Expert reviewTable 1
Deﬁnition of the ICH M7 hazard classiﬁcations.
Class Deﬁnition
1 Known mutagenic carcinogens
2 Known mutagens with unknown carcinogenic
3 Alerting structure, unrelated to the structure
4 Alerting structure, same alert in drug substan
mutagenic
5 No structural alerts, or alerting structure with
a Or other relevant positive mutagenicity data indic
1 The term “(Q)SAR” refers to (Quantitative) Struct
is used as an acronym for computational models that
(such as mutagenicity) based on the chemical struct
term collectively refers to both quantitative and non-q
relationships by placing the “Q” in parentheses.elucidates scenarios where additional expert knowledge may be beneﬁcial, what such an expert review
may contain, and how the results and accompanying considerations may be documented. Furthermore,
the use of these principles and procedures to yield a consistent and robust (Q)SAR-based argument to
support impurity qualiﬁcation for regulatory purposes is described in this manuscript.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The ICH M7 guideline (“Assessment and control of DNA reactive
(mutagenic) impurities in pharmaceuticals to limit potential
carcinogenic risk”) provides a framework for assessing and con-
trolling DNA reactive impurities in a pharmaceutical product (ICH
M7, 2015a). The guideline describes the process whereby actual
and potential impurities or degradation products likely to be pre-
sent in the drug substance and drug product are identiﬁed and
outlines how a hazard assessment should be performed. When no
adequate experimental mutagenicity and/or carcinogenicity
results are available, a structure-based computational toxicology or
(Q)SAR1 analysis may be able to predict the mutagenic potential of
an impurity. The hazard assessment process leads to the assign-
ment of each impurity to one of ﬁve classes described in Table 1.
Brieﬂy, class 1 impurities are to be controlled “… at or below
compound-speciﬁc acceptable limit” (ICH M7, 2015b), class 2 or 3
impurities are to be controlled at or below acceptable limits
(appropriate Threshold of Toxicological Concern or TTC) and classes
4 and 5 are to be treated as non-mutagenic impurities (ICH M7,
2015a; Kasper and Müller, 2015).
Prior to the publication of ICH M7, many regional guidance
documents and scientiﬁc papers were published, each contributing
to the thought process followed in a mutagenic impurity risk
assessment (EMA, 2006, 2010; FDA, 2008; Müller et al., 2006). This
included regulatory guidance documents from the European
Medicines Agency (EMA, 2006, 2010) and a draft guidance from the
US Food and Drug Administration (FDA, 2008) that outlined a
methodology for assessing DNA-reactive compounds based on
available data as well as mutagenicity predictions from (Q)SAR
models. Sutter et al. (2013) outlined the different (Q)SAR method-
ologies available and highlighted the importance of applying expert
knowledge to predictions, a concept also discussed by Dobo et al.
(2012), Kruhlak et al. (2012), Naven et al. (2012), Barber et al.
(2015) and Stavitskaya et al. (2015). Dobo et al. (2012) demon-
strated improved accuracy with expert input on negative pre-
dictions. Powley (2015), Greene et al. (2015), Stavitskaya et al.
(2015) and Barber et al. (2015) recently provided additionalpotential (bacterial mutagenicity
of the drug substance; no mutagen
ce or compounds related to the dr
sufﬁcient data to demonstrate lac
ative of DNA-reactivity-related ind
ure-Activity Relationship and
predict a biological response
ure of the test molecule. The
uantitative structure-activitydetails concerning the use of expert knowledge in the context of an
ICH M7 (Q)SAR analysis and Powley (2015) provided general rec-
ommendations concerning the format and content of a (Q)SAR
analysis report to support regulatory submission.
The ICH M7 guideline is currently being implemented
throughout the pharmaceutical industry and international regula-
tory agencies. A number of speciﬁc difﬁculties are being encoun-
tered that are not fully addressed in existing publications. These
include: (1) the process of assessing the adequacy of sufﬁcient
in vivo and/or in vitro data; (2) the generation of an overall
assessment from the two (Q)SARmethodologies which individually
generate positive, negative, or inconclusive predictions as well as
out-of-domain classiﬁcations; (3) when to apply expert knowledge
that could potentially refute a (Q)SAR prediction; (4) what rationale
may be considered for use in such an expert review; and (5) an
outline for a standardized report to ensure the results are consis-
tently documented, transparent and complete.
Fig. 1 summarizes the process of implementing a (Q)SAR anal-
ysis of potential mutagenic impurities. The ﬁrst step is to collect any
relevant data from public sources (such as from the literature) for
each impurity. This information can be supplementedwith relevant
in-house test results. In general, adequate negative bacterial
mutagenicity and/or carcinogenicity laboratory data are sufﬁcient
to assign the impurity to class 5, whereas adequate positive data
would result in assigning the impurity to classes 1 or 2. The ade-
quacy of the data used in these classiﬁcations should be critically
reviewed. In the absence of adequate data, a (Q)SAR analysis may be
used for this class assignment. The (Q)SAR results are used to assign
the impurity to ICH M7 classes 3e5. This may include the genera-
tion of an expert review to accept or refute any predictions. Positive
overall assessments are assigned to class 3, with negative overall
assessments generally assigned to class 5; however, where a spe-
ciﬁc argument based on shared alerts with a compound known to
be non-mutagenic is made, these compounds may be assigned to
class 4.
This paper outlines a number of practical principles and pro-
cedures that can be used in generating a (Q)SAR assessment aligned
with ICH M7 as part of a regulatory submission, including accom-positive,a no rodent carcinogenicity data)
icity data
ug substance (e.g., process intermediates) which have been tested and are non-
k of mutagenicity or carcinogenicity
uction of gene mutations (e.g., positive ﬁndings in in vivo gene mutation studies).panying expert analysis. The paper provides a brief overview of the
process of identifying and reviewing available data from public and
in-house databases as well as the literature. In the absence of
adequate data, the principles for combining the (Q)SAR results from
Fig. 1. Flow chart depicting an ICH M7 (Q)SAR assessment.
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discuss when and how to generate a supplemental expert review
that may concur with or refute any prediction. A series of case
studies are presented to illustrate the different principles and
procedures described. Many of these case studies are from phar-
maceutical projects but have not been reviewed or accepted by a
regulatory authority unless stated otherwise. This paper will also
provide suggestions detailing the contents of an expert analysis and
delineate its inclusion in a regulatory submission.2. Assessing available data
According to the ICHM7 guideline (ICHM7, 2015a), the ﬁrst step
in the hazard assessment is “… database and literature searches for
carcinogenicity and bacterial mutagenicity data …” Since data may
have been generated within a pharmaceutical manufacturer's or-
ganization, a search of proprietary in-house data may be performed
alongside open access or commercial database searches. Table 2
lists a number of open access and commercial databases contain-
ing mutagenicity and/or carcinogenicity data. Since it is unrealistic
to search all possible databases individually, utilizing a database
containing up-to-date information from many of these sources
provides a useful alternative. A number of such services are
described in Table 2.
In addition ICH recently published a draft addendum to ICH M7.
Includedwithin this addendum are a series of permissible limits for
a range of commonly used reagents (ICH M7, 2015b).
The focus of ICH M7 is on DNA-reactive impurities, which are
generally identiﬁed using the Bacterial Reverse Mutation Assay,
commonly referred to as the Ames assay (OECD, 1997). An Ames
assay may have been performed on the speciﬁc impurity, either by
the pharmaceutical manufacturer or identiﬁed from a search of
open access or commercial databases. Any results from a database
search should return information necessary to understand the
adequacy of the study. An adequately performed negative bacterial
mutagenicity study is generally sufﬁcient to assign the impurity to
class 5, which is treated as a non-mutagenic impurity. Positive re-
sults may be used to assign the impurity to class 2 (known muta-
gens with unknown carcinogenic potential). The adequacy of any
Ames data used in both the class 2 or class 5 assignments should be
critically reviewed as discussed in Greene et al. (2015), in line with
the principles of Klimisch (Klimisch et al., 1997) as well as be
generally consistent with the discussion in Note 2 of the ICH M7
guideline (ICH M7, 2015a). These publications indicate that the
Ames test data should be available for inspection and should
include at least ﬁve strains of bacteria, including four strains of
S. typhimurium (TA1535; TA1537 or TA97a or TA97; TA98; andTA100) as well as Escherichia coli WP2 strains or Salmonella typhi-
murium TA102 (which are similar in mutation detection), exposed
to the test substance both in the presence and absence of an
appropriate metabolic activation system, with concentrations for
soluble non-cytotoxic substances up to 5 mg/plate or 5 ml/plate.
Studies pre-dating the publication of the OECD guideline are
generally acceptable when they were performed in a manner
consistent with the OECD guideline (OECD, 1997).
Pending sufﬁcient justiﬁcation (e.g., difﬁcult to synthesize im-
purities), data from other study designs, using fewer test strains or
lower drug concentrations, may be used when the quality of the
data and study design is considered appropriate. Decisions to
accept suboptimal assays may be inﬂuenced by an analysis of the
risk versus the beneﬁt. Deviations from the standard test protocols
are acceptable in certain situations, for example, where a limited
number of strains have been tested yet it has been shown that those
strains are sensitive to any identiﬁed structural alert, as outlined in
Note 2 of the ICH M7 guideline (ICH M7, 2015a). The assessment of
data may also take into account structural classes that result in false
positives under certain experimental conditions, such as an inter-
action between a test material containing an acid halide or sulfonyl
halide and DMSO in the Ames test (Amberg et al., 2015). It should
be noted that Ames data tested on a limited number of strains may
be considered as part of the weight of evidence in any accompa-
nying expert analysis. Validation statistics of limited strain models
can be used to support the expert analysis (Diehl et al., 2000; Zeiger
et al., 1985). Other reported genetic toxicity testing battery results
are not generally relevant in this context, but may be considered on
a case-by-case basis when no or inadequate Ames data are avail-
able, such as, positive mouse lymphoma studies with increases in
large colonies, when the assay and data meet up to date criteria for
positive results (OECD 490, 2015).
The ICH M7 Addendum (Step 2) discusses what factors consti-
tute an adequate rodent carcinogenicity study (ICH M7, 2015b). An
adequate negative rodent carcinogenicity study is sufﬁcient to
categorize the impurity as class 5. A positive result with evidence of
a mutagenic mechanism from an adequately performed study may
be used to categorize the compound as class 1 (known mutagenic
carcinogen). There may also be situations where a compound is
positive in the rodent carcinogenicity study and negative in the
bacterial mutagenicity study. For example, carcinogens that are
negative in the bacterial mutation study may act through a non-
mutagenic mechanism such as by causing hormonal imbalance or
proliferative changes leading to cancer. When mechanisms are
clearly demonstrated, these cases are considered outside the scope
of ICHM7.When a genotoxic threshold is demonstrated per ICHM7
in an in vivo follow-up test e.g. rat micronucleus, a Permissible Daily
Table 2
Databases containing information on carcinogenicity and mutagenicity data.
Database Description Reference
ATSDR Open access database from the Agency for Toxic Substances and Disease Registry (ATSDR) includes toxicological
proﬁles for the hazardous substances including genotoxicity
ATSDR, 2015
CCRIS Open access database covering chemical carcinogens, including structures and experimental data, covering the period
1985e2011
Young, 2002; CCRIS, 2011
CPDB Open access Carcinogenicity Potency DataBase covering the period 1980e2011 Gold, 1997, 2001, 2005; CPDB
2011
DSSTox Open access Distributed Structure-Searchable Toxicity (DSSTox) Database Network including content from other
sources (e.g. CPDB, ISSCAN)
DSSTox-Archive, 2012
ECHA Open access European Chemicals Agency (ECHA) database containing actual data and read across results for chemicals
manufactured and imported in Europe
ECHA, 2015
ExPub Commercial application that includes access to the GENE-TOX and CCRIS databases ExPub, 2015
GENE-TOX GENE-TOX provides genetic toxicology (mutagenicity) test data from expert peer review of open scientiﬁc literature for
more than 3000 chemicals from the United States Environmental Protection Agency (EPA)
GENE-TOX, 1998
IARC Open access International Agency for Research on Cancer (IARC) monographs including carcinogenicity classiﬁcation IARC, 2015
IPS INCHEM Open access International Program on Chemical Safety search for variety of summary documents INCHEM, 2015
IRIS Open access data from the EPA in support of human health risk assessment, focusing on hazard identiﬁcation and dose
eresponse assessment
IRIS, 2015
ISSCAN Open access database on chemical carcinogens, including structures and experimental data from Istituto Superiore di
Sanita
Benigni et al., 2008
JECDB Open access Japanese Existing Chemical Data Base (JECDB) containing high production volume chemicals JECDB, 2015
Leadscope Commercial genetic toxicity and rodent carcinogenicity databases from numerous sources (including US FDA CDER
product approval reviews, FDA CFSAN, NTP, CCRIS, and so on) as well as ongoing data harvesting from the literature.
Currently includes genetic toxicity data for 11,028 compounds and 179,732 test results and rodent carcinogenicity data
for 3598 compounds and 11,538 test results.
Leadscope, 2015
MultiCASE QSARmodel training sets containingmutagenicity and rodent carcinogenicity data from public and proprietary sources
including the FDA, GENETOX, NTP, CCRIS and IARC.
MultiCASE, 2015
NTP Open access database of National Toxicology Program results Tennant, 1991; NTP, 2015
PAN Open access Pesticide Action Network (PAN) Pesticide Database PAN, 2014
Pharma Pendium Commercial toxicity data from FDA and EMA approval documents Pharmapendium, 2015
RTECS Commercial database available through third parties (e.g. Leadscope) currently containing 10,517 Tumorigenic studies
for 3724 compounds and 46,385 Mutation studies for 13,343 compounds
Sweet, 1999; RTECS, 2015
ToxNet/
ChemIDPlus
Open access on-line toxicity search system from the US National Library ofMedicine with access to archived versions of
CCRIS, GENE-TOX, CPDB
Wexler, 2001; ToxNet, 2015
TRACE from
BIBRA
Commercial service for TRACE includes information from peer-reviewed toxicology and nutrition journals as well as
secondary sources and websites. In addition to the primary literature on the health effects of chemicals, TRACE covers
ofﬁcial publications and evaluations issued by authoritative groups.
Anderson, 2000; BIBRA, 2015;
Robinson, 2000
VITIC from Lhasa
Limited
Commercial data from published and unpublished sources (15,000 records for carcinogenicity and nearly 95,000
records with mutagenicity Ames data) from a number of sources including IARC Monographs, European Chemicals
Bureau (IUCLID) and NTP.
VITIC, 2015
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2.1. Case study 1: identifying a compound with historical data
In case study 1, a public database search identiﬁed a historical
bacterial mutagenicity studywith a negative result for the impurity,
as shown in Fig. 2. This search identiﬁed a 5-strain Ames study by
which the compound may be assigned to class 5 due to sufﬁcient
evidence for absence of mutagenicity in an adequately performed
in vitro reverse mutation assay.Fig. 2. Example 1 showing the r3. Generating (Q)SAR predictions
In the absence of sufﬁcient experimental mutagenicity and/or
carcinogenicity data for a speciﬁc impurity, the ICH M7 guideline
recommends the use of (Q)SAR models for evaluating the muta-
genic potential. This (Q)SAR assessment should utilize models that
focus on “… bacterial mutagenicity predictions…” and the guideline
suggests the use of the two complementary methodologies: “expert
rule-based” and “statistical-based.” The guideline goes on to state
that the “… (Q)SAR models … should follow the general validationesults of a database search.
A. Amberg et al. / Regulatory Toxicology and Pharmacology 77 (2016) 13e24 17principles set forth by the Organisation for Economic Co-operation and
Development (OECD).” (OECD, 2007a)
Commonly used statistical-based models include the Leadscope
Genetox Statistical QSAR, CASE Ultra from MultiCASE, Inc., and
Sarah Nexus from Lhasa Limited and commonly used expert rule-
based methodologies include the Leadscope Genetox Expert
Alerts and Derek Nexus from Lhasa Limited. The most recent
version of each model is preferred for the (Q)SAR analysis; how-
ever, it is generally accepted that there are limited changes between
different versions and that in practice there are few if any reported
changes in overall predictions, in particular of negative predictions
being reversed. Recommendations for setting computational model
parameters have been provided by Stavitskaya et al., 2013. For
example (at the time of publication), with the Leadscope expert-
rule based methodology (Leadscope Model Applier: Genetox
Expert Alerts Suite), the domain assessment should be turned on,
and with the Leadscope statistical-based methodology (Leadscope
Model Applier: Genetox Statistical (Q)SAR Suite) probabilities  0.6
set to positive, probabilities < 0.4 set to negative and the domain
assessment turned on.
(Q)SAR models adhering to OECD principles would ideally
generate the following prediction results that can be used directly
to assess the individual impurities: positive (predicted to be
mutagenic) and negative (predicted to be non-mutagenic). How-
ever, there are a number of reasons why a (Q)SAR model does not
always generate such a classiﬁcation. The ﬁrst reason is that the
systemmay determine that the impurity is out-of-domain, that is, it
is incapable of making a prediction since the system does not
adequately cover the structural features of the impurity (OECD
validation principle #3). The second reason is that the prediction
results may be categorized as equivocal or indeterminate due to
weak or conﬂicting evidence, such that a deﬁnitive prediction
cannot be made with adequate conﬁdence. The third is where a
prediction system is technically unable to process certain types of
chemicals, such as for coordination compounds.24. Considerations for an overall assessment and expert review
4.1. Overview
The ICH M7 guideline states that the “… absence of structural
alerts …” from the two suggested (Q)SAR methodologies is sufﬁ-
cient to assign the impurity to class 5. Since any individual meth-
odology may generate results such as a positive prediction, a
negative prediction, an inconclusive prediction, or an out-of-
domain assignment, it is important to consider how these indi-
vidual results may be used to derive an overall mutagenic or non-
mutagenic assessment consistent with the language in the guide-
line. The ICHM7 guideline goes on to state that the results from the
(Q)SARmethodologies may, if warranted, be examined further. This
expert review may provide “… additional supportive evidence on
relevance of any positive, negative, conﬂicting or inconclusive pre-
diction and provide a rationale to support the ﬁnal conclusion.” (ICH
M7, 2015a) This review has been shown to improve performance
(Stavitskaya et al., 2015; Sutter et al., 2013) and provide a basis for
refuting the (Q)SAR results (Powley, 2015; Stavitskaya et al., 2015;
Barber et al., 2015). The following sections outline a series of gen-
eral principles that describe (1) how an overall assessment may be
performed, (2) when an expert review may be provided, and (3)
what such an expert analysis may contain.2 A coordination complex or metal complex consists of a central atom or ion
(generally metallic) and a surrounding array of bound molecules or ions.4.2. Negative assessments and expert reviews
A regulatory evaluation of potentially mutagenic impurities
should allow for the analysis of many compounds while main-
taining a high degree of sensitivity. This can reasonably be achieved
using negative predictions from two recommended (Q)SAR meth-
odologies for each compound, without the need for a detailed
expert analysis, as long as the methodologies use an automated
domain assessment. If additional veriﬁcation is desired, a rapid
visual inspection of the results by the expert can be used to verify
that no valid alerts for mutagenicity with a plausible mechanism
were overlooked by the two (Q)SAR methodologies (Powley, 2015;
Barber et al., 2015).
4.2.1. Case study 2: clear negative prediction from two
methodologies
In Fig. 3, the depicted impurity was automatically determined to
be within the applicability domain of both the expert rule-based
and the statistical-based models and negative predictions were
generated by both methodologies. The statistical-based model
considered all atoms and bonds in the analysis (i.e., in this
modelling system, no atoms or bonds appear in black) as shown in
Fig. 3. A quick review of this information may be sufﬁcient to
conclude that the overall prediction for this impurity is non-
mutagenic and it can be assigned to class 5.
4.2.2. Case study 3: refuted negative prediction from two
methodologies
O-(2-Hydroxyethyl)hydroxylamine is shown in Fig. 4 and had a
negative prediction for bacterial mutagenicity using both the
expert rule-based and the statistical-based models. However, there
is conﬂicting evidence for the mutagenic response of different hy-
droxylamine salts in the public domain. It was therefore concluded
that a potential mutagenic response on the basis of the hydroxyl-
amine moiety should be further evaluated. O-(2-Hydroxyethyl)
hydroxylamine was submitted for Ames assay testing where it
induced mutations in strain TA1535 in the absence of S9.
When a negative prediction is made in only a single method-
ology and an inconclusive prediction or an out-of-domain assign-
ment made in the second methodology, it may be necessary to
inspect the results in more detail before generating an overall
conclusion. Both situations are discussed in Sections 4.4 and 4.5.
4.3. Positive prediction and expert reviews
A positive prediction from either of the methodologies may lead
to an overall positive prediction. Positive predictions may be
refuted through an expert analysis, if appropriate. There are several
issues to consider when writing an expert review refuting positive
(Q)SAR results including the relevance of any alerting features or
corresponding training set compounds, the ability of the chemical
environment proximate to the alerting feature to mitigate the
mutagenicity and information from chemical analogs (Powley,
2015; Stavitskaya et al., 2015; Barber et al., 2015). A positive
assessment may be based on results from a single or multipleFig. 3. Example 2. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 4. Example 3 (O-(2-Hydroxyethyl)hydroxylamine).
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the underlying reasons for the positive result may be different. The
following sections outline different points to be considered when
refuting a positive prediction.
4.3.1. Shared alert with known negative (ICH M7 class 4)
The ICH M7 guideline includes the following statement: “An
impurity with a structural alert that is shared (e.g., same structural
alert in the same position and chemical environment) with the drug
substance or related compounds can be considered as non-mutagenic
… if the testing of such material in the bacterial mutagenicity assay
was negative.” (ICH M7, 2015a) The ﬁrst step is to identify the
structural basis for the impurity's (Q)SAR result (from the matched
expert rule and/or the statistical-based model(s)). Next, a related
compound with negative Ames data (such as the Active Pharma-
ceutical Ingredient or API, or another related impurity) is identiﬁed
that also contains the same highlighted structural features (“known
negative”). The following questions may then be asked:
 Are there any additional structural alerts present in the impurity
that are not present in the known negative comparator com-
pound? If so, it may not be possible to completely refute the
positive (Q)SAR result and apply the class 4 argument.
 Is the alert in the same chemical environment in the impurity as
in the comparator compound? Chemical reactivity of an alerting
moiety may be mitigated by the presence of another feature in
both molecules. Factors to consider in this comparison include
(1) differences in the electron charge density (i.e. electron rich
or electron deﬁcient) around the speciﬁc alerting structure, (2)
the steric environment proximal to the alerting structure, (3) the
solubility or (4) the size or shape of the impurity.4.3.1.1. Case study 4: refuting a positive prediction based on an ICH
M7 class 4 analysis. Fig. 5 represents a series of similar impurities
that were predicted to be positive in the statistical-based model.
The common features responsible for the positive prediction are
summarized and highlighted in red in Fig. 5. 5-strain GLPAmes data
conducted according to OEDC 471 and ICH S2(R1) guidelines were
generated for one structure (known negative) and were applied to
other impurities where R, R1, R2 or R3 varied but without addi-
tional alerting functionality (shown in Fig. 5). The impurities in case
study 4 are considered analogs of the known negative compound
and all share the same highlighted positive structural features. The
known negative comparator in combination with negative pre-
dictions in the expert rule-based model was sufﬁcient to predictFig. 5. A series of chemicals all predicted to be positive in a statistical-based model
based on the feature highlighted in red. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)that the impurities would also be non-mutagenic and should be
assigned to class 4.
4.3.1.2. Case study 5: refuting a positive prediction based on an ICH
M7 class 4 analysis. Example 5 (shown in Fig. 6) was predicted to be
positive by both the expert rule-based and the statistical-based
models as a result of the primary aromatic amine (highlighted in
red). The most relevant and structurally similar analog in the rule-
based alert system, and the only analog containing a similarly
substituted aniline as is present in the test structure, was experi-
mentally negative for bacterial mutation (shown in Fig. 6) (NTP,
1980). It has been reported that the triﬂuoromethyl groups in the
meta position to the amine are strongly deactivating for mutage-
nicity (Ahlberg et al., 2016). The most analogous structure from the
alert in the statistical model was run in a different rule-based
system and was predicted negative, since it contains a strong
deactivating group. Example 5 is also fully contained within the
drug substance, for which the GLP Ames assay was negative. The
weight-of-evidence suggests that it is unlikely to be mutagenic and
was therefore assigned to class 4. This expert review has been
reviewed and accepted by a regulatory authority.
4.3.2. An explanation of the mechanism
A positive prediction is triggered by an alert or a signiﬁcant
statistical-based model feature that is present in the impurity. This
fragment's associated mutagenic potential may be based on a
reasonable mechanistic rationale and/or there may be sufﬁcient
positive examples matching the fragment; however, the environ-
ment around the alerting moiety within this speciﬁc impurity may
preclude reaction at this site. It is possible to construct an expert
review to refute the prediction (Powley, 2015; Stavitskaya et al.,
2015; Barber et al., 2015). In situations where a compound is pre-
dicted negative by an expert rule-basedmethodology, yet predicted
positive by a statistical-based methodology, it may be helpful to
understandwhy the compound containing any highlighted group is
not positive in the expert rule-based system. Does the alert deﬁ-
nition contain any exceptions to the rule?
4.3.2.1. Case study 6: refuting a positive prediction based on a
mechanism analysis. In Example 6, the potential impurity was
predicted to be positive by the statistical-based model but negative
by the expert rule-based model. As shown in Fig. 7, the main
contribution to the positive prediction by the statistical-based
model was the feature highlighted in red. In reviewing the com-
pounds supporting the alerting fragment, it was found that the
alerting fragment was highly inﬂuenced by the mutagenicity data
on alkyl sulfonate esters, dialkyl sulfates, or sultones (see Fig. 8),
which are known alerts for mutagenicity (Ashby and Tennant,
1988; Benigni and Bossa, 2008). Example 6 is a mono-alkyl sul-
fate esters; these are consistently negative in the Ames assay
(OECD, 2007b) and are not alkylating agents. Mono-alkyl sulfate
esters are negatively charged at physiological pH and therefore are
less electrophilic than their alkyl sulfonate counterparts. The
mono-alkyl sulfate esters in the training set were also non-Fig. 6. Example 5 and analog. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. Example 6 predicted to be positive in the statistical-based methodology, pri-
marily based on the feature highlighted in red. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 8. Structural deﬁnitions for alkyl sulfonate esters, dialkyl sulfates, and sultones.
Fig. 9. Example 7 with features contributing to the positive prediction highlighted in
red. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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mutagenic poly aromatic hydrocarbons such as benz(a)anthracene
and chrysene. Therefore, Example 6 is predicted to be non-
mutagenic.
4.3.3. The relevance of features from statistical-based
methodologies
A positive prediction from a statistical-based model may be
refuted if the structural features that are the basis for the “alert” in
the model (“positive contributing features”) are not relevant,
illustrated as follows:
 Coincidental features: Structural features are identiﬁed
through machine-learning when building statistical-based
models. Positive features are identiﬁed when present in a
group of predominantly mutagenic training set compounds.
However, these mutagenic compounds could also contain other
structural features that better represent the actual moiety
responsible for the observed mutagenicity. In these cases, the
statistical model has identiﬁed coincidental features. If the
positive predictionwas based primarily upon these coincidental
features then an expert analysis refuting the prediction may be
made (Powley, 2015; Barber et al., 2015). One example of such a
situation is where an amine oxide is ﬂagged in a set of aromatic
nitro compounds.
 Mitigating features: A positive prediction may be refuted if the
positive model features are mitigated by negative features
present at or proximal to the same reaction center.
 Limited training set examples: It is possible that a positive
model feature was derived from a small number of examples. An
expert analysis may refute a positive prediction made primarily
using such features.
 No signiﬁcant positive model features: The positive prediction
may result from very small contributions from many unrelated
or unconnected positive model features.
 Irrelevant training set examples: It is possible that a positive
model feature was derived from a set of compounds covering
multiple structural classes. It is also possible that some of these
structural classes do not apply to the speciﬁc impurity (they are
part of a different chemical series) and an expert review to
refute the positive prediction may be an option if the impurity is
within one of the non-mutagenic chemical classes.
 Underlying data are incorrect or not adequate: It may be
possible to identify model features based on data that are not
correct as a result of certain experimental conditions, such as aninteraction between a test material containing an acid halide or
sulfonyl halide and DMSO in the Ames test (Amberg et al., 2015).4.3.3.1. Case study 7: refuting a positive prediction based on a
mechanism and coincidental features. In this example the potential
impurity was predicted to be positive by the statistical-based
model but negative by the expert rule-based model. Example 7 is
an N-oxide of a non-aromatic amine bearing a phenyl/aryl group.
The major contributing features are highlighted in red in Fig. 9.
Firstly, the training sets inadequately represent N-oxide of a non-
aromatic amine bearing a phenyl/aryl group, whose predicted
mutagenic activity was inﬂuenced by other co-occurring alerting
features. Secondly, the literature indicates that the tertiary alkyl
amine N-oxides are non-mutagenic. Finally, a structural analysis
was performed for mutagenicity on nitrogenous aryl compounds
and their corresponding N-oxides using TRPþ reversion in E. coli
(Pai et al., 1978). This structural analysis included 10 tertiary aryl
amines and their corresponding N-oxides. As part of the weight of
the evidence, it was concluded that primary aromatic amines and
their corresponding hydroxylamines, and N-hydroxycarbamates
were mutagenic, but not the tertiary aryl amines or their corre-
sponding tertiary N-oxides, as shown in Fig. 10 (Pai et al., 1978).
Hypothetically, dealkylation of the amine to yield a primary aro-
matic amine is a potential mechanism of mutagenicity; however, in
case study 7, this would yield aniline, which is known to lack
mutagenic potential. The lack of mutagenicity following deal-
kylation is further supported by the observation that the parent
drug substance (API) structure contains the corresponding primary
aromatic amine and was negative in the bacterial reverse mutation
assay. Based on analysis of the training sets, a negative expert rule-
based prediction, literature analysis for tertiary amine N-oxides,
and its structural similarity to the drug substance, Example 7 is
predicted to be non-mutagenic.
4.3.3.2. Case study 8: refuting a positive prediction based on coinci-
dental features. Example 8 is shown in Fig. 11 and was predicted to
be positive by the statistical-based model and negative by the
expert rule-based model. An expert review of Example 8 described
below concluded that the probability of mutagenicity is low based
on a review of the training set and a comparison with the drug
substance, which was negative in the bacterial reverse mutation
assay. The most relevant model features were evaluated and found
to contain examples of another alert more likely to be responsible
for the positive prediction (see supplemental material for more
details). These features included a planar anthracene-like tricyclic
aromatic core; however, the polycyclic core of Example 8 is puck-
ered, due to the presence of sp3 carbon atoms, with CeH bonds
almost orthogonal to either plane deﬁned by any two fused rings,
hence making the structure non-planar. Example 8 was therefore
predicted to be non-mutagenic.
4.3.3.3. Expert reviews based on chemical analogs from public or in-
house sources. Experimental Ames data for structural analogs can
Fig. 10. Structural deﬁnitions for primary aromatic amines and their corresponding hydroxylamines, and N-hydroxycarbamates as well as tertiary aryl amines and corresponding
tertiary N-oxides.
Fig. 11. Example 8.
A. Amberg et al. / Regulatory Toxicology and Pharmacology 77 (2016) 13e2420also be used when the training sets do not contain suitable
numbers of related structures (Powley, 2015; Barber et al., 2015;
Stavitskaya et al., 2015). Sufﬁciently similar analogs from the liter-
ature, public databases or in-house information may be used to
provide justiﬁcation for refuting a positive or overruling an
inconclusive prediction. The number of analogs and the degree of
structural similarity needs to be assessed on a case-by-case basis
(Powley, 2015).4.3.3.4. Case study 9: refuting a positive prediction using data from
chemical analogs. Example 9 was predicted to be positive by the
statistical-based methodology and negative by the expert rule-
based methodology. A database search identiﬁed a number of
close analogs as shown in Fig. 12. All analogs were experimentally
non-mutagenic in the Ames assay. The extension of the carbon side
chain of Example 9 should not increase its reactivity compared to
the analogs. Example 9 is therefore predicted to be non-mutagenic.
This compound, in fact, has been shown to be experimentally
negative for bacterial mutagenicity (Carmellino, 1993). This
example is used to illustrate the concept of an analog search and, as
part of this analysis, it is necessary to assess the adequacy of the
underlying Ames data.4.4. Expert reviews for inconclusive (Q)SAR results
Inconclusive predictions are generated when there is not
enough evidence to make a mutagenic or non-mutagenic predic-
tionwith adequate conﬁdence. In general, all approaches discussed
earlier to refute a positive or negative prediction can reasonably be
applied to an inconclusive prediction for a covered (i.e., within the
applicability domain) compound in an attempt to resolve the pre-
diction and generate a negative or positive overall conclusion. The
following outlines several potential approaches to assessing the
results as part of an expert review to reach a conclusion that the
impurity is likely mutagenic or non-mutagenic.Fig. 12. Example 9 with analogs. Visual inspection by an expert: One approach to assess
inconclusive predictions is for a chemist or toxicologist to
visually inspect the results to verify there are no valid alerts for
mutagenicity with a plausible mechanism. For example, the
chemist or toxicologist who is visually inspecting the results
may have knowledge of mutagenicity alerts and/or mechanisms
derived from proprietary data not built into the (Q)SAR models.
It may be important to consider portions of the molecule (e.g.
functional groups) not represented in the (Q)SAR models. Sys-
tematic substructural searching of functional groups not
considered by the models may also support the identiﬁcation of
features that are positively associated with bacterial mutage-
nicity data (i.e. there is a statistically signiﬁcantly greater
number of positive examples than would be expected by
chance). The expert may also consider whether the structural
features highlighted by the statistical-based models show sig-
niﬁcant association with bacterial mutagenicity.
 Strength of a single prediction: Where only a single method-
ology has generated a prediction, an assessment of the strength
of this prediction may be made to determine whether it is suf-
ﬁcient as the basis of an overall conclusion.4.4.1. Case study 10: assessing an inconclusive prediction using the
literature
Example 10 (Fig. 13) was predicted to be negative by the expert
rule-based methodology and inconclusive by the statistical-based
methodology; in the latter the most signiﬁcant contribution was
from the primary aromatic amine. As discussed in Ahlberg et al.
(2016), primary aromatic amines are mutagenic only in the pres-
ence of an activating functional group. Both functional groups (the
bromo group in the para position and the carboxylate in the ortho
position) are not activating according to Ahlberg et al. (2016) (based
on an analysis of primary aromatic amine data from public and
proprietary databases) and therefore Example 10 was predicted to
be non-mutagenic. This compound has been tested in a standard
Ames assay using 5 strains and is non-mutagenic (Greene et al.,
2015).
4.4.2. Case study 11: assessing an inconclusive prediction using
analogs
Example 11 (shown in Fig. 14) was predicted to be negative by
the expert rule-based model and inconclusive by the statistical-
based model. Since Example 11 contains a hydrazine substructure
and speciﬁc classes of hydrazines are known to be mutagenic, an
analysis based on the evaluation of published Ames assay data forFig. 13. Example 10.
Fig. 14. Example 11 with analog.
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identiﬁcation of numerous structural analogs tested in the Ames
assay including the analog shown in Fig. 14 that was reported to be
mutagenic. Hence, Example 11 was predicted to be mutagenic.4.5. Expert reviews for “out of domain” statements
When an impurity is presented to a model that is sufﬁciently
different from the types of chemicals used in the reference/training
set, the model should not make a prediction, in accordance with
OECD validation principle #3. These out-of-domain results, how-
ever, may also be assessed as part of an expert review. As back-
ground to the analysis, it may be helpful to understand why the
model was unable to make a prediction for this speciﬁc impurity. In
a similar manner to inconclusive results that were discussed earlier,
it may be possible to generate an expert review for an out-of-
domain result based on: (1) a visual inspection by an expert
chemist or toxicologist, (2) an assessment of the strength of a
prediction by a single methodology, (3) an understanding of rele-
vant mutagenic mechanisms, and (4) data for structural analogs.
Another approach that may be helpful in assessing this type of
result is to investigate whether the out-of-domain result is attrib-
utable to the addition of a non-reactive group. The ﬁrst step as part
of this assessment is to determine if there are any similar chemicals
that were predicted negative or where there is a negative experi-
mental result. If the only difference from the out-of-domain
structure is the addition of a non-reactive group (e.g. an amine
protected by two tert-butoxycarbonyl (Boc) groups or other non-
alerting fragment) and as long as this group could not cause an
additional functional group to become an activated alert, then this
scenario may be used to address an out-of-domain situation.
Running another model is also an option to address an out-of-
domain or indeterminate (Q)SAR prediction; however, it should
be noted that running a third model is not required by ICH M7.
Similar to the ﬁrst two models, the third model should also follow
the OECD (2007a) (Q)SAR validation principles to ensure that one is
simply not running models until one with a less stringent appli-
cability domain calculation is found.4.5.1. Case study 12: assessing an out-of-domain response based on
the mechanism
Example 12 is a large compound containing greater than 30
non-hydrogen atoms (Fig. 15). Example 12 was determined to be
out-of-domain by the statistical-based model. The example also
contains an aromatic amine moiety which is structurally alerting.Fig. 15. Example 12 (>30 non-hydrogen atoms).The mechanism of mutagenicity associated with aromatic amines
requires oxidation by cytochrome P450 to hydroxylamines and
then further activation by O-acylation. The O-acylated N-arylhy-
droxylamine is converted to a highly electrophilic nitrenium ion,
which then reacts with DNA (Benigni and Bossa, 2011). Aromatic
amines found within pharmaceutical intermediates are more likely
to be negative in the bacterial mutation assay than those that have
data available in the public literature, according to an analysis of in-
house databases (McCarren et al., 2011). This has been attributed to
the bias towards larger molecular weight compounds in drug
development with increased steric hindrance to formation of the
reactive mutagenic metabolite or decreased ability of the metabo-
lite to cross bacterial cell walls (Glende et al., 2002; Hatch et al.,
2001; Benigni, 2005). For example, it has been reported that the
addition of bulky alkyl groups away from the amino group changes
a mutagenic aromatic amine to a non-mutagenic species (Glende
et al., 2002). Hydrolysis or metabolism to generate a small aro-
matic amine that may be mutagenic is not possible in Example 12.
Therefore, Example 12 is predicted to be non-mutagenic due to the
size of the compound which results in a potential lower bioavail-
ability, and inhibited formation of the putative reactive nitrenium
metabolite.
4.5.2. Case study 13: assessing an out-of-domain prediction using a
similar analog
Example 13 was out-of-domain by the statistical-based models
and predicted to be negative by the expert rule-based model.
Example 13 (shown in Fig. 16) is very similar to the drug substance,
which was also out-of-domain for the statistical based models. The
change in position was concluded not to change the potential for
mutagenic reactivity, since there were no alerting features on the
drug substance or the impurity (based on the expert rule-based
model). Therefore, based on its structural similarity to the drug
substance (which was negative for bacterial mutagenicity in the
Ames assay), Example 13 was predicted to be non-mutagenic.
Case study 13 illustrates an expert analysis based on a change of
a substituent position. Changes in the position of heteroatoms
within the ring can also be important to consider. For example, 3-
Aminoisoxazole is non-mutagenic and 5-amino-4-chloro-3-
methylisoxazole is mutagenic, as shown in Fig. 17. Both are exam-
ples of primary aromatic amines, where the aromatic system is a 5-
membered heterocycle and both rings contain a single nitrogen and
oxygen; however, the position of these heteroatoms is different in
the two compounds relative to the primary aromatic amine. These
compounds, along with an analysis of the structure-activity rela-
tionship, are discussed in Ahlberg et al. (2016).
4.5.3. Case study 14: assessing an out-of-domain prediction using
public analogs
Aminoacetonitrile (Example 14) was out-of-domain for the
statistical-based models and predicted to be negative by the expert
rule-based model. No standardized Ames testing has been per-
formed with aminoacetonitrile. However, data from structurallyFig. 16. Example 13 alongside the drug substance which is negative in the Ames assay.
Fig. 17. Examples of how the position of heteroatoms may inﬂuence mutagenicity.
Fig. 18. Example 14 with analogs (including Ames results).
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This included 3-aminopropionitrile (Analog 2) that was tested
negative in TA98, TA100, TA1535, TA1537, and TA1538 with and
without metabolic activation. (CCRIS 3-aminopropionitrile) The
single analog that was mutagenic (3-chloropropionitrile) contains
an additional alerting structure (monofunctional alkyl chloride) not
shared with aminoacetonitrile. In addition to these nearest neigh-
bors, aminoacetonitrile is also structurally similar to cyanamide
which is also non-mutagenic in a 5-strain Ames assay with E. coli
(FIOSH, 2014). Therefore, Example 14 was predicted to be non-
mutagenic.4.5.4. Case study 15: assessing an out-of-domain based on the
addition of a non-reactive group
Example 15 is the Boc protected form of Compound Y (shown in
Fig. 19). Example 15 was predicted to be negative by the expert rule-
based methodology but out-of-domain for the statistical-based
methodology. Compound Y was predicted to be negative in the
statistical-based methodology. Boc protection is used to prevent
chemical reactivity of the secondary amine and can be cleaved under
acidic conditions (Schelhass and Waldmann, 1996). Therefore,
Example 15 is also not predicted to be mutagenic given its similarity
and reduced chemical reactivity compared to Compound Y.
Situations can arise where it is not possible to generate a (Q)SAR
prediction with either methodology due to the impurity being out-
of-domain, or both methodologies returning inconclusive pre-
dictions. When no model is able to generate a prediction, aFig. 19. Example 15 with analog Y (predicted negative).pragmatic approach would be to either perform an Ames test or
assign the impurity to class 3. However, in situations when no
experimental data are generated, expert knowledge could be used
to supersede even these predicted outcomes, with the caveat that it
should include justiﬁable scientiﬁc evidence for regulatory
acceptance.
4.5.5. Case study 16: assessing an out-of-domain result from two
methodologies
Example 16 (shown in Fig. 20) was concluded to be out-of-
domain by both the expert rule-based and the statistical-based
models as a result of the novelty of the R-group. Example 16 is
similar to the drug substance; the only difference is that the pri-
mary amine group of the drug substance has been has been con-
verted to the bis-boc imide, shown in Fig. 20, through Boc
protection of the primary amine. The drug substance is also
concluded to be out-of-domain by both (Q)SAR methodologies;
however, it has been tested and is non-mutagenic in the standard
5-strain Ames test. Since there is no expected reactivity from the
bis-boc functionality, Example 16 is predicted to be non-mutagenic
(which was conﬁrmed experimentally in a standard 5 strain Ames
assay). As in Case Study 14, given the bis-boc protection serves to
reduce reactivity, it could be reasonable to classify this as a non-
mutagenic compound despite the lack of predictions in both
methodologies.
5. Reporting
The ﬁnal report may include a description of the methodologies
used, a summary of the results along with any expert reviews that
should be transparent and “include supporting information to arrive
at the overall conclusion for Class 4 and Class 5 impurities” (ICH M7,
2015a). The selection of the impurities to be reported is depen-
dent on the stage of development, as shown in Table 3, which
presents a summary from the ICH M7 guideline.
The following elements may be included in the report of a
(Q)SAR assessment consistent with ICH M7 with the level of detail
dependent on the stage of development:
1. Materials and methods
 Software, models and databases used, along with version
numbers and parameters set
2. Summary of the results and conclusions
 Chemical structure of the impurity that may include high-
lighting to illustrate what the software has identiﬁed as
structural features associated with or not associated with
positive bacterial mutagenicity data (when this highlighting
can be generated automatically by the system)
 Experimental data and/or (Q)SAR results from both method-
ologies (the experimental and (Q)SAR results may be in
different tables or sections)
 Overall conclusion based on the prediction results and any
expert review (i.e., mutagenic or non-mutagenic) along with
class 1e5 assignmentFig. 20. Example 16 alongside the non-mutagenic drug substance.
Table 3
Reporting requirements at each development phase.
Development phase Reporting requirements
Phase 1 clinical trials of 14 days or less Class 1 and class 2 impurities; cohorts of concern
Phase 1 clinical greater than 14 days or Phase
2a clinical trials
Class 1, class 2 and class 3 impurities; cohorts of concern
Phase 2b clinical trials or Phase 3 clinical
trials
List of actual/potential impurities assessed by (Q)SAR, Class 1, class 2 and class 3 impurities; plan for control, bacterial
mutagenicity test results.
Common Technical Document (Marketing
Application)
List of actual/potential impurities assessed by (Q)SAR, Class 1, class 2, class 3, class 4, and class 5 impurities; supporting
information, plan for control, bacterial mutagenicity study reports.
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3. Supporting information
 Expert review(s) supporting or refuting the (Q)SAR result,
along with examples and references to illustrate
4. References, especially those used to support an expert review, if
applicable
5. Appendices
 Complete bacterial mutagenicity study reports at the time of
marketing application may be included in the appendices or
cross-referenced or hyperlinked from another section
When models are used that are not familiar to regulatory
agencies, it will be necessary to provide additional documentation
showing how these models are consistent with the OECD (Q)SAR
validation principles (OECD, 2007a). The supplemental information
contains an example of a regulatory submission using examples
described above.
6. Conclusions
The ICH M7 guideline provides a framework for assessing DNA
reactive impurities and describes how these impurities may be
controlled. This framework is currently being implemented across
the pharmaceutical industry and international regulatory agencies.
An important component of this guideline is the use of (Q)SAR as an
alternative to conventional testing for the assessment of the
mutagenic potential of drug substance impurities. (Q)SAR models
represent a state-of-the art approach to predicting mutagenicity
that balances the need for high-throughput while maximizing pa-
tient safety.
This paper has outlined a number of practical principles and
procedures to be considered when conducting a (Q)SAR analysis
consistent with the ICH M7 guideline. This includes, in the absence
of adequate experimental data, how to combine the results from
the recommended (Q)SAR models, when to consider generation of
a detailed expert review, and what such a review may contain. The
contents of a full report for inclusion as part of a regulatory sub-
mission have been outlined. Through adoption of common princi-
ples and procedures, the practical implementation of a (Q)SAR
analysis consistent with the ICH M7 guideline will become more
standardized, consistent, and transparent. Additionally, the gener-
ation and review of these reports should become more streamlined
over time for both pharmaceutical manufacturers and regulatory
agencies.
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